Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial

      During the past 15 years, improvements in the field of allogeneic hematopoietic stem cell transplantation (HSCT) significantly extended its feasibility. However, disease recurrence after HSCT remains a main issue. Thus, prophylactic interventions such as unmanipulated donor lymphocytes infusions (DLI) are frequently used post-HSCT, but their potential benefit may be counterbalanced by the induction of GvHD. In this setting, the use of adoptive ex vivo activated NK cell infusions from the same donor (DLI-NK) may induce GVL effect without causing GvHD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect